Document is current
Any future updates will be listed below
-
Authors
Jayakrishnan, Thejus T. http://orcid.org/0000-0002-3636-0353
Sangwan, Naseer
Barot, Shimoli V. http://orcid.org/0000-0002-5313-9992
Farha, Nicole
Mariam, Arshiya
Xiang, Shao
Aucejo, Federico
Conces, Madison
Nair, Kanika G.
Krishnamurthi, Smitha S.
Schmit, Stephanie L.
Liska, David
Rotroff, Daniel M.
Khorana, Alok A.
Kamath, Suneel D. http://orcid.org/0000-0003-0432-2536
-
Funding
Funding for this research was provided by:
The Sondra and Stephen Hardis Chair in Oncology Research
- License Information
-
More Information
Article History
Received: 25 February 2024
Accepted: 9 July 2024
First Online: 17 July 2024
Competing interests
: The authors declare the following competing financial and non-financial interests—S.S.K.: Consulting or Advisory Role—Array BioPharma, Takeda Research funding—Bristol Myers Squibb, Pfizer, Aravive, Natera; S.L.S.: No disclosures; D.L.: Consulting or Advisory Role—Olympus Medical Systems, Research funding—Merck, Freenome; D.M.R.: Equity stake in Clarified Precision Medicine, LLC. Received research support from Novo Nordisk, consulting honoraria from Pharmazam, LLC, and Interpares Biomedicine owns intellectual property related to the detection of type-2 diabetes, chronic liver disease, and liver cancer; S.D.K.: Consulting or advisory role: Exelixis, Guardant Health. Tempus, SeaGen, Foundation Medicine, Takeda. Speaking: SeaGen, Merck, Takeda, AstraZeneca; A.A.K.: honoraria—Sanofi, BMS, Anthos, Pfizer, Bayer, and WebMD. Consulting or advisory role: Sanofi, BMS, Anthos, Pfizer, Bayer, and WebMD. Other authors declare no competing financial or non-financial interests.
